URGP.OB: Summary for URIGEN PHARMACEUTCLS - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 12:25am EST - Canadian Markets open in 9 hours and 5 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Urigen Pharmaceuticals, Inc. (URGP.OB)

On Feb 9: 0.15 USD 0.00 (0.00%)

MORE ON URGP.OB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

URIGEN PHARMACEUTCLS (OTC BB:URGP.OB) Delayed quote data

Last Trade:	0.15 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	0.15
Open:	0.15
Bid:	0.14 x 5000
Ask:	0.15 x 5000
1y Target Est:	9.00

Day's Range:	0.14 - 0.15
52wk Range:	0.05 - 0.19
Volume:	13,000
Avg Vol (3m):	147,337
Market Cap:	11.06M
P/E (ttm):	N/A
EPS (ttm):	-0.03
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add URGP.OB to Portfolio

Download Data

HEADLINES

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Fri, Jan 15)

•	Dan Vickery, PhD Joins Urigens Board
	Business Wire (Thu, Jan 14)

•	Prof. Lowell Parsons Presents Urigen at One Med Place Conference in San Francisco on Jan. 13 at 4PM
	Business Wire (Wed, Jan 13)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exh
	EDGAR Online (Thu, Dec 31)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
	EDGAR Online (Mon, Dec 21)

•	Urigen & Oceana Collaborate on FDA Meeting Preparation
	Business Wire (Mon, Dec 21)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Mon, Dec 7)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 16)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
	EDGAR Online (Thu, Oct 29)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
	EDGAR Online (Wed, Oct 28)

More Headlines for URGP.OB...

ANALYST

EPS Est (next year) (Dec-69) :	N/A
EPS Est (in 2 years) (Dec-69) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products for urological disorders. Its products include URG101, which completed Phase II clinical trial for the treatment of painful bladder ...

Full Company Profile

Add to Portfolio

Email to a Friend

•